Olon ac­quires man­u­fac­tur­ing fa­cil­ity in In­dia

BioSpectrum (India) - - COMPANY NEWS -

Ital­ian com­pany Olon S.p.A., a world lead­ing Ac­tive Phar­ma­ceu­ti­cal In­gre­di­ents (API) con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CDMO) and gener­ics sup­plier, has an­nounced the ac­qui­si­tion of a lo­cal gener­ics chem­i­cal op­er­a­tions API man­u­fac­tur­ing fa­cil­ity in Ma­had, In­dia, as part of a con­tin­u­ing ex­pan­sion of its global foot­print.

Ac­cord­ing to Paolo Tu­ber­tini, CEO of Olon, by ac­quir­ing a man­u­fac­tur­ing base in In­dia, Olon will have the op­por­tu­nity to ac­cel­er­ate growth by adding new CDMO projects and to de­velop new generic prod­ucts for the In­dian mar­ket.

The Ma­had site, which sup­plies prod­ucts to San­doz, a divi­sion of the No­var­tis Group, is an es­tab­lished and rep­utable API man­u­fac­tur­ing fa­cil­ity in In­dia and pro­vides a num­ber of life­sav­ing medicines to the In­dian health­care sys­tem and pa­tients around the world. As part of the as­set pur­chase agree­ment, the par­ties have com­mit­ted to sign a long-term sup­ply con­tract to guar­an­tee con­tin­u­ous sup­ply of San­doz prod­ucts man­u­fac­tured in Ma­had. No im­pact on jobs is planned and Olon in­tends to in­vest in the site and pur­sue busi­ness de­vel­op­ment op­por­tu­ni­ties to op­ti­mize the plant’s uti­liza­tion and ex­pand its cus­tomer base. The ac­qui­si­tion of the Ma­had API man­u­fac­tur­ing fa­cil­ity is ex­pected to be com­pleted in early 2019, fol­low­ing a tran­si­tion process.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.